Ophthalmic compositions

• US 20020045601A1
• Filed: 08/27/2001
• Published: 04/18/2002
• Est. Priority Date: 05/13/1992
• Status: Active Grant

• Current Assignee: Mitsuaki Kuwano, Yoichi Kawashima
• Original Assignee: Mitsuaki Kuwano, Yoichi Kawashima
• Inventors: Kawashima, Yoichi, Kuwano, Mitsuaki
• Granted Patent: US 6,582,718 B2
• Time in Patent Office: Days
• US Class Current: 514/100
• CPC Class Codes: A61K 38/13 Cyclosporins
• CPC Class Codes: A61K 9/0048 Eye, e.g. artificial tears
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: A61P 27/14 Decongestants or antiallergics
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 37/02 Immunomodulators
• CPC Class Codes: Y02A 50/30 Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

An ophthalmic composition particularly in the form of eye-drops suitable for the treatment of diseases of the eye and surrounding areas. The composition contains a cyclosporin and a surfactant selected from polyoxyethylene fatty acid esters, polyoxyethylene alkylphenyl ethers and polyoxyethylene alkyl ethers, or mixtures thereof.

Claims

1. An ophthalmic composition comprising a cyclosporin and a surfactant selected from polyoxyethylene fatty acid esters, polyoxyethylene alkylphenyl ethers and polyoxyethylene alkyl ethers, or mixtures thereof.

2. An ophthalmic composition according to claim 1 and further comprising a thickening agent.

3. An ophthalmic composition according to claim 2 in which the thickening agent is selected from cellulose thickening agents, carboxyvinyl polymers, polyvinyl polymers and polyvinylpyrrolidones.

4. An ophthalmic composition according to claim 1 comprising from about 0.01 to about 0.075% (w/v) of cyclosporin A;

(1) from about 0.15 to about 2.5% (w/v) of polyoxyl 40 stearate;

(2) from about 0.1 to about 3.0% (w/v) of a cellulose thickening agent selected from hydroxypropyl methylcellulose or hydroxyethylcellulose; and

(3) from about 0.0001 to about 0.01% (w/v) of an anti-oxidant selected from butylated hydroxytoluene or sodium thiosulfate.

5. An ophthalmic composition according to any one of claims 1 to 4 further comprising an aqueous carrier.

6. An ophthalmic composition according to any one of claims 1 to 3 in which the cyclosporin is cyclosporin A.

7. An ophthalmic composition according to any one of claims 1 to 4 in a container appropriate for topical ophthalmic application of the composition.

8. A method of treating a disease or condition of the eye or of the surrounding or associated organs or tissues in a subject in need thereof, which method comprises administering a composition according to any one of claims 1 to 4 topically to the eye.

9. An ophthalmic composition as claimed in any one of claims 1 to 4 for use in a method of treating a disease or condition of the eye or of the surrounding or associated organs or tissues in a subject in need thereof.

10. A cyclosporin for use in the preparation of a composition as claimed in any one of claims 1 to 4.